Investor Area

Home / Investor Area / Nomura update “Statistically significant results – will progress to a Phase IIb”

Nomura update “Statistically significant results – will progress to a Phase IIb”

CUV announced successful, statistically significant results from its US Phase IIa pilot study (CUV102) of its afamelanotide 16mg implant in the pigmentation disorder Vitiligo.